The Optipharm-CKM Programme
👤 Authors: Riccardo M Inciardi, Muthiah Vaduganathan, Carlo M Lombardi, Cristina Gussago, Piergiuseppe Agostoni, Pietro Ameri, Nadia Aspromonte, Leonardo Calò, Matteo Cameli, Erberto Carluccio, Stefano Carugo, Manlio Cipriani, Raffaele De Caterina, Gaetano M De Ferrari, Michele Emdin, Alessandra Fornaro, Marco Guazzi, Massimo Iacoviello, Massimo Imazio, Maria Teresa La Rovere, Sergio Leonardi, Marta Maccallini, Daniele Masarone, Luigi Moschini, Alberto Palazzuoli, Giuseppe Patti, Roberto F E Pedretti, Pasquale Perrone Filardi , Massimo F Piepoli, Luciano Potena, Andrea Salzano, Angela Sciacqua, Michele Senni, Gianfranco Sinagra, Claudia Specchia, Stefano Taddei, Dario Vizza, Gianluigi Savarese, Giuseppe Rosano, Maurizio Volterrani, Marco Metra; on behalf of the OPTIPHARM‐HF Investigators
ABSTRACT:
On behalf of the San Raffaele University (uniroma-5), the Italian Heart Failure Association (ITAHFA) and Heart Success Foundation (HFS)
The Optipharm Registry focuses on improving care for patients with cardiovascular, kidney, and metabolic conditions (CKM), which are closely linked and major causes of death and disability worldwide. These include heart disease, kidney disease, and type 2 diabetes. Many people with heart failure (HF) also have these conditions, especially those with mildly reduced or preserved heart function, and this can lead to worse health outcomes.
In 2023, the American Heart Association introduced a new framework called CKM syndrome to help identify and understand this overlap. Around 90% of adults in the U.S. have some form of CKM syndrome, with 15% experiencing more advanced stages. Treatment for CKM conditions has become more effective thanks to newer medications, but many patients are still not receiving the care they need, often due to issues like treatment delays, cost, or side effects.
The Optipharm Registry aims to collect real-world data to understand how these conditions are treated across different regions and how well current guidelines are being followed. By doing so, it will help identify barriers to effective treatment and improve patient care worldwide, focusing on heart disease, diabetes, kidney disease, and heart failure
.
